WOIPPY, FRANCE, July 16, 2024 /EINPresswire.com/ — ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the execution of an exclusive distribution agreement to confer to Interlux OÜ (https://www.linkedin.com/company/interlux-estonia/ ) the rights to promote and commercialize ABLD assays and software systems to all laboratories in Estonia.
Through this new partnership, Interlux OÜ is now able to offer microbiology laboratories PCR assays and secured downstream analysis software systems validated on Capillary Electrophoresis (SANGER) and various Next Generation Sequencing (NGS) workflows.
The agreement also covers generic NGS library preparation reagents suited to various systems that can be acquired by Life Sciences labs involved in DNA sequencing for any application like oncology, human genetics.
“ABL Diagnostics & the Interlux Group are partners for a long time in Lithuania. We are proud to expand this collaboration in Estonia and join forces to offer robust and competitive solutions to labs involved in molecular biology“ said Audrius Tutlys, General Manager at Interlux OÜ.
“Over the last years, we have been able to develop nice synergies with Interlux and are now eager to move our collaboration one step forward and help microbiology experts in Estonia with our DeepChek solution.” added Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics.
ABL Diagnostics strives to reinforce its commercial strategy with a growing network of local exclusive partners (https://www.abldiagnostics.com/distributors/) in more than 50 countries in Africa, Asia, Europe, Middle East and, South America, to offer end-to-end solutions for Microbiology genotyping through SANGER and NGS workflows.
The detailed terms of the agreement have not been disclosed.